Biochemical and Biophysical Research Communications
Volume 263, Issue 2, 24 September 1999, Pages 340-345
Regular ArticleInhibitory Effect of Full-Length Human Endostatin on in Vitro Angiogenesis☆
References (29)
- et al.
J. Biol. Chem.
(1992) - et al.
Cell
(1996) - et al.
Biochem. Biophys. Res. Commun.
(1989) J. Biol. Chem.
(1996)- et al.
FEBS Lett.
(1997) - et al.
Anal. Biochem.
(1987) Nature Medicine
(1995)Nature
(1997)N. Engl. J. Med.
(1995)- et al.
Science
(1983)
Proc. Natl. Acad Sci. USA
(1989)
J. Cell Biol.
(1995)
Endocr. Rev.
(1997)
Endocr. Rev.
(1997)
Cited by (93)
A versatile microfluidic platform for the study of cellular interactions between endothelial cells and neutrophils
2017, Biochimica et Biophysica Acta - General SubjectsEndostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
2015, Biochimica et Biophysica Acta - General SubjectsCitation Excerpt :Both endogenously produced endostatin and Endostar, recombinant human endostatin, can inhibit angiogenesis in vivo [156]. In mouse models, endostatin has been shown to suppress and even completely inhibit the tumor mass growth rate though inhibition of angiogenesis [163,164]. Although not extensively studied, the results of in vivo experiments support endostatin's anti-lymphangiogenic role based on its inhibition of bFGF-induced lymphangiogenesis [165].
Angiogenesis in cutaneous disease: Part I
2009, Journal of the American Academy of DermatologyThe endothelium in lung fibrosis: a core signaling hub in disease pathogenesis?
2023, American Journal of Physiology - Cell Physiology
- ☆
Abbreviations used: CVEC, capillary venular endothelial cells; FGF-2, fibroblast growth factor 2; VEGF/VPF, vascular endothelial growth factor/vascular permeability factor
- 1
To whom correspondence should be addressed. Fax: 39-055-4222725. E-mail: [email protected].
Copyright © 1999 Academic Press. All rights reserved.